Jefferies remains reluctant to take its rating on Twitter to "Sell" because of its recent turnaround efforts.

Shares of Twitter (TWTR) were sinking over 1% in pre-market trading on Friday after investment firm Jefferies cut its rating on the beleaguered social media company's stock to "Hold" from Buy" with a $16 price target.

While Twitter's platform does carry "broad user engagement" monetization is weakening, Jefferies analyst Brent Thill noted. "In social we see a clear winner in [Facebook (FB) ]."

"TWTR's push to be a digital live video provider is interesting, but we note that bigger competitors such as FB & [Alphabet (GOOGL) ] have much stronger digital video propositions for advertisers with much larger and more engaged user bases, deeper granular data for targeting, and proven return on advertiser investment," Thill said.

Unfortunately for Twitter, not only are engagement improvements not translating into increased revenue, advertising revenues in the first half of the year sunk 6%, he added.

But, Tahill did not take the stock to a "Sell" because of improvements made the past two years.

"We believe recent management changes could help improve the declining [average revenue per user] in the near term," he said. "We will pay close attention to advertiser sentiment over coming months and effectiveness of live video."

Facebook and Alphabet are holdings in Jim Cramer's Action Alerts PLUS Charitable Trust Portfolio . Want to be alerted before Cramer and the AAP team buy or sell FB or GOOGL? Learn more now .

Don't miss these top stories on TheStreet:

More from Stocks

Netflix Stock: Why I'm Keeping My Bird Box Blindfold On

Netflix Stock: Why I'm Keeping My Bird Box Blindfold On

Investors Who Couldn't Wait to Dump Stocks Now Can't Buy Them Fast Enough

Investors Who Couldn't Wait to Dump Stocks Now Can't Buy Them Fast Enough

16 Stocks Jim Cramer Says Could Win from a U.S.-Chinese Trade Deal

16 Stocks Jim Cramer Says Could Win from a U.S.-Chinese Trade Deal

Eli Lilly Slides as Sarcoma Treatment Fails in Phase 3 Trial

Eli Lilly Slides as Sarcoma Treatment Fails in Phase 3 Trial

VF Corp. Surges on Back of Strong Earnings, Raised Guidance

VF Corp. Surges on Back of Strong Earnings, Raised Guidance